Poniard Pharmaceuticals (PARD) Reports Positive Efficacy and Safety Data from Phase 2 Trials on Picoplatin
Tweet Send to a Friend
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced positive incremental data from its ongoing Phase 2 clinical trial of picoplatin in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
